Horizon Discovery is a global leader in gene editing, specializing in the design and engineering of genetically modified cells used in cutting-edge research and clinical applications aimed at improving human health. At the core of Horizon’s capabilities is its proprietary translational genomics platform, which integrates a powerful suite of gene editing technologies—including CRISPR, ZFN (zinc finger nucleases), and rAAV (recombinant adeno-associated virus). These tools allow precise, targeted modifications of virtually any gene in human or mammalian cell lines.

With a portfolio of more than 25,000 catalog products and research services, Horizon enables scientists to model genetic diseases with high accuracy. Most of these offerings are based on advanced cell and animal models that closely mimic the genetic mutations found in conditions like cancer, helping accelerate drug discovery and development.

Now part of Horizon Discovery, Dharmacon is a recognized pioneer in RNA interference (RNAi) and custom RNA synthesis. Dharmacon played a foundational role in developing the first commercially available siRNA reagents and contributed significantly to the early science of RNAi. Today, the brand offers a comprehensive suite of RNAi tools—including siRNA, lentiviral shRNA, microRNA research tools, and genome-scale libraries for high-throughput functional screening of genes, microRNAs, and long non-coding RNAs. In addition, Dharmacon provides one of the largest commercially available collections of cDNAs and ORFs for gene overexpression studies.

Together, Horizon Discovery and Dharmacon provide researchers with an integrated toolbox for exploring gene function, modeling disease, and developing targeted therapies that advance human health.